Pulmotect
Jump to navigation
Jump to search
PULMOTECT is a clinical-stage pharmaceutical company developing PUL-042, a drug that stimulates the innate immune system in the lungs, which could provide short-term elevated capability to defend the body against inhaled pathogenic threats. While that application of technology is broad (and includes asthma, bioterror, pandemics and other indication), the Companys initial clinical program is focused on patients at uniquely high risk for airborne infection, including leukemia patients enduring regimes of chemotherapy and organ transplant patients, who become immune-compromised as part of the transplant regime.
| Pulmotect | |
|---|---|
| Startup Information | |
| Website | http://pulmotect.com/ |
| Industry | |
| Accelerator | Fannin Innovation Studio |
| Accelerator (Other) | |
| Founder | |
| Founding Date | |
| Street Address | |
| City | |
| Zip Code | |
| Copyright © 2016 McNair Center. All Rights Reserved. | |
